---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004845"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T06:02:22.355354+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enanta Pharma Q4 net loss $24.6M; FY net loss $79M; terminates HBV asset, plans COVID protease inhibitor

## Summary
- Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.
- FY revenue $97.1M (down 21% from $122.5M); net loss $79M ($3.92 loss per diluted share) vs $36.2M loss.
- Terminated EDP-721 (HBV RNA destabilizer) due to adverse safety signals; positive Phase 1b data for EDP-514 HBV core inhibitor.
- Plans to advance EDP-235 oral protease inhibitor for COVID-19 into Phase 1 in early 2022.
- Discontinued internal NASH FXR agonist development; will pursue out-licensing; FY2022 guidance: R&D $150-170M, G&A $35-41M.

## SEC filing metadata
- accession: 0000950170-21-004845
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/0000950170-21-004845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/enta-20211122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004845
- JSON: https://secwatch.observer/filing/0000950170-21-004845.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.